Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher


Patrick Forde, M.B.B.Ch.

Photo of Dr. Patrick Forde, M.B.B.Ch.
  • Director, Thoracic Cancer Clinical Research Program
  • Associate Professor of Oncology

Languages: English, Irish


Clinical Trials, Lung Cancer, Medical Oncology, Mesothelioma, Non-Small Cell Lung Cancer, Pulmonary Carcinoid Tumors, Small Cell Lung Cancer more

Research Interests

Lung Cancer; Mesothelioma; Clinical Investigation


Skip Viragh Outpatient Cancer Center

201 N. Broadway
Baltimore, MD 21287 map
Phone: 410-955-8893 | Fax: 410-614-9334

Johns Hopkins Bayview Medical Center

300 Mason Lord Drive
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD 21224 map
Phone: 410-550-1711 | Fax: 410-550-1116


Dr. Forde treats patients with lung cancer, mesothelioma and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Associate Member of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Director of Clinical Research for lung cancer, mesothelioma, and other thoracic cancers at Johns Hopkins.

He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for earlier stage lung cancer and his work has led to the development of several ongoing phase 3 trials. 

He leads several international phase 2 and 3 clinical trials of novel immunotherapy approaches for lung cancer and mesothelioma that are currently active in Europe, Asia and North America while also serving as principal investigator for the thoracic cancer immunobiology biospecimen repository at Johns Hopkins. He is focused on providing compassionate, state of the art care for his patients in conjunction with a team of oncology specialist nurses, nurse practitioners and dedicated staff. more


  • Director, Thoracic Cancer Clinical Research Program
  • Associate Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MBBCh, Royal College of Surgeons in Ireland (2004)


  • Royal College of Physicians Ireland / Internal Medicine (2007)
  • Mater Misericordiae University Hospital / Medical Oncology (2008)
  • Beaumont Hospital / Medical Oncology (2009)


  • Cork University Hospital / Medical Oncology (2010)
  • St James's Hospital / Medical Oncology (2011)
  • Johns Hopkins University School of Medicine / Oncology (2014)

Research & Publications

Selected Publications

View all on Pubmed

Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018 May 24;378(21):1976-1986. PMID:29658848

Cottrell TR, Thompson ED, Forde PM, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018 Aug 1;29(8):1853-1860 PMID: 29982279

Anagnostou V, Forde PM, White JR, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res. 2019 Mar 15;79(6):1214-1225. PMID: 30541742

Rosner S, Reuss JE, Forde PM. PD-1 Blockade in Early-Stage Lung Cancer. Annu Rev Med. 2019 Jan 27;70:425-435. PMID: 30355264

Activities & Honors


  • Fellowship Award, International Association for the Study of Lung Cancer (IASLC), 2013
  • Career Development Award, LUNGevity Lung Cancer Foundation, 2014 - 2017
  • Paul Carbone MD Fellowship Award, 2013
  • Director's Teaching Award in Clinical Science, SKCCC, 2014 - 2015
  • AACR-SU2C Phillip A. Sharp Innovation in Collaboration Award, 2016
  • ESMO Travel Award, 2016


  • American Society of Clinical Oncology
  • International Association for the Study of Lung Cancer
  • Society for Immunotherapy of Cancer

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button